Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T45083
(Former ID: TTDI01792)
|
|||||
Target Name |
Tryptophan 5-hydroxylase (TPH)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Irritable bowel syndrome [ICD-11: DD91] | |||||
BioChemical Class |
Paired donor oxygen oxidoreductase
|
|||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | LX-1031 | Drug Info | Phase 2 | Irritable bowel syndrome | [2] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Inhibitor | [+] 1 Inhibitor drugs | + | ||||
1 | LX-1031 | Drug Info | [1] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome. IDrugs. 2010 Dec;13(12):921-8. | |||||
REF 2 | ClinicalTrials.gov (NCT00813098) Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.